AlphAIAlphAI — Financial news for AI agents
pharmaphorum.comNOV 32 min read

Merck charts course out of CDMO business with Lonza sale

Merck KGaA is selling its CDMO business to Lonza for a mid-triple-digit million-euro amount, including five US facilities and 1,100 employees. The deal aims to sharpen Merck's life sciences focus and free up resources for other areas, including pharmaceuticals. Lonza expects the acquisition to add $300 million in annual revenue starting in 2028. The transaction is expected to close in mid-2027.

Original reporting
pharmaphorum.com
Published Nov 3, 2026, 10:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Merck charts course out of CDMO business with Lonza sale — source image
Source · pharmaphorum.com
Decision brief

The 30-second read

Med
01

Why it matters

The transaction reshapes the CDMO landscape, giving Lonza a larger US presence and new technology platforms, while providing Merck with cash to fund R&D and other strategic initiatives.

02

Market read

The deal is a material M&A event that could move Lonza's stock higher and impact Merck's valuation as it reallocates capital.

03

What to watch

Closing in 2027 may delay market reaction; integration risk of US sites could affect execution.

Relevance 9/10Novelty 9/10Timing: today

Background

Merck KGaA is refocusing on its core life‑sciences and pharmaceutical businesses, while Lonza seeks to grow its CDMO capabilities.

Market effects

Sector

Strengthens the CDMO sector, may pressure peers like Thermo Fisher and Catalent.

Regional

Positive for European biotech equipment suppliers and Swiss pharma stocks.

Global

Highlights continued consolidation in contract manufacturing, relevant to global pharma supply chains.

Counterpoint

What could challenge this read

Deal could strain Merck KGaA's cash flow and distract from its core life‑sciences business.

Key entities

  • company
    Merck KGaA

    German life‑sciences group selling its CDMO unit.

  • company
    Lonza Group AG

    Swiss contract manufacturing firm acquiring the CDMO business.

Read at source← All news

StoryLonza to acquire Merck KGaA’s five U.S. CDMO sites

Also covered by

6 outlets

Related articles

NOV 3
HighAI 8/10

Lonza buys 5 sites from Germany’s Merck to more than double US footprint

Lonza agreed to buy five U.S. manufacturing sites from Merck KGaA for 100-600 million Swiss francs, expanding its U.S. footprint to nine sites. The deal, expected to close mid-2024, adds 1,100 employees and is projected to generate 250 million francs in annual sales by 2028. Lonza gains cancer and gene therapy production capabilities, while Merck focuses on drug development.

investing.com2 min
NOV 3
MedAI 8/10

Merck KgaA divests US CDMO business to Lonza

Merck KGaA is selling its US contract development and manufacturing organization (CDMO) business to Lonza for an estimated low- to mid-triple-digit million Swiss francs. The deal includes five US sites and around 1,100 employees, expected to close mid-2024. Lonza anticipates $300m in sales from these facilities by 2028. Merck aims to focus on innovation-driven life sciences businesses, according to the company.

manufacturingchemist.com2 min
NOV 3
MedAI 8/10

Lonza to acquire five US manufacturing sites from Merck KGaA

Lonza will acquire five US manufacturing sites from Merck KGaA for low- to mid-triple-digit millions of Swiss francs. The deal, expected to close in mid-2027, will expand Lonza's US presence and add 1,100 employees. The sites focus on various pharmaceutical technologies, with Lonza expecting them to contribute around SFr250m in sales by 2028. The acquisition aligns with Lonza's growth strategy, according to the company.

pharmaceutical-technology.com2 min
NOV 3
HighAI 9/10

Lonza Group To Buy Merck's CDMO Business

Lonza Group agreed to buy five U.S. CDMO sites from Merck KGaA for low-to-mid-triple-digit million Swiss francs, payable in cash. The deal, expected to close in mid-2027, will expand Lonza's U.S. footprint and add capabilities in antibody-drug conjugates and gene therapies. The acquired sites are projected to generate CHF 250 million in sales in 2028.

rttnews.com2 min